Page last updated: 2024-11-08

bay 41-4109

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

BAY 41-4109: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID489221
CHEMBL ID605300
SCHEMBL ID13886906
MeSH IDM0437129

Synonyms (25)

Synonym
bay41-4109
bay 41-4109
5-pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, methyl ester, (4r)-
methyl (4r)-4-(2-chloro-4-fluoro-phenyl)-2-(3,5-difluoro-2-pyridyl)-6-methyl-1,4-dihydropyrimidine-5-carboxylate
CHEMBL605300 ,
bay-414109
methyl (4r)-4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoropyridin-2-yl)-6-methyl-1,4-dihydropyrimidine-5-carboxylate
(-)-bay-41-4109
unii-m862i4t61o
m862i4t61o ,
bay-41-4109
298708-81-3
SCHEMBL13886906
HY-100029
CS-6426
EX-A7415
bdbm50278715
Q27283615
MS-26664
(r)-bay 41-4109
(r)-methyl 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoropyridin-2-yl)-6-methyl-1,4-dihydropyrimidine-5-carboxylate
YLA70881
methyl (4r)-4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-methyl-5-pyrimidinecarboxylate
DTXSID401107166
AKOS040732549

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Pharmacokinetic studies in mice have shown rapid absorption, a bioavailability of 30% and dose-proportional plasma concentrations."( Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model.
Deres, K; Goldmann, S; Graef, E; Haebich, D; Hagelschuer, I; Hartmann, E; Niewoehner, U; Paessens, A; Ruebsamen-Waigmann, H; Schlemmer, KH; Stoltefuss, J; Weber, O; Wohlfeil, S, 2002
)
0.31
" The purpose of the current research work was to develop and evaluate Bay41-4109 loaded chitosan nanoparticles to increase the solubility and bioavailability for treatment of HBV."( Development of chitosan nanoparticles as drug delivery system for a prototype capsid inhibitor.
An, S; Guo, Y; Hou, H; Hu, S; Jiang, C; Jiang, X; Lu, Y; Xue, M; Zhang, Y; Zhou, X, 2015
)
0.42
" In particular, the (2S,4S)-4,4-difluoroproline substituted analogue 34a demonstrated high oral bioavailability and liver exposure and achieved over 2 log viral load reduction in a hydrodynamic injected (HDI) HBV mouse model."( Design and Synthesis of Orally Bioavailable 4-Methyl Heteroaryldihydropyrimidine Based Hepatitis B Virus (HBV) Capsid Inhibitors.
Chen, W; Guo, L; Huang, M; Jiang, M; Lin, X; Liu, H; Liu, Y; Mao, Y; Mayweg, AV; Qin, N; Qiu, H; Qiu, Z; Ren, S; Shen, F; Shen, HC; Shi, L; Tang, G; Wu, G; Wu, JZ; Wu, X; Xu, Z; Yang, G; Yang, W; Zhang, W; Zhang, Y; Zhong, S; Zhou, M; Zhou, X; Zhou, Z; Zhu, W, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PPM1D proteinHomo sapiens (human)Potency20.82120.00529.466132.9993AID1347411
Interferon betaHomo sapiens (human)Potency20.82120.00339.158239.8107AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Capsid protein Hepatitis B virusIC50 (µMol)0.43000.10000.26500.4300AID1502484
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Capsid protein Hepatitis B virusEC50 (µMol)0.04800.00020.26030.8194AID1363957
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Capsid protein Hepatitis B virusEC90 (µMol)0.10200.10200.10200.1020AID1363957
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (30)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (43)

Assay IDTitleYearJournalArticle
AID1363962Cytotoxicity in human HepG2.215 cells assessed as reduction in cell viability after 5 days by CCK8 assay2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4).
AID1363957Inhibition of hepatitis B virus capsid assembly infected in human HepG2.215 cells assessed as reduction in viral DNA replication measured on day 7 by real time PCR analysis2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4).
AID1502484Inhibition of HBV C150-Bodipy FL N-(2-aminoethyl) maleimide labeled capsid assessed as reduction in NaCl-induced capsid assembly preincubated for 15 mins followed by NaCl addition measured after 1 hr by fluorescence quenching assay
AID1661463Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as reduction in capsid associated DNAs at 1 uM by agarose gel electrophoresis method
AID1859023Antiviral activity against HBV infected in human HepDES19 cells assessed effect on intracellular total HBV RNA at 2 uM measured after 24 hrs by northern blot hybridization assay2022Bioorganic & medicinal chemistry letters, 02-15, Volume: 584-Oxooctahydroquinoline-1(2H)-carboxamides as hepatitis B virus (HBV) capsid core protein assembly modulators.
AID1631932Antiviral activity against Hepatitis B virus infected in human HepDE19 cells assessed as reduction in viral DNA level after 5 days by dot blot assay2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Design and Synthesis of Orally Bioavailable 4-Methyl Heteroaryldihydropyrimidine Based Hepatitis B Virus (HBV) Capsid Inhibitors.
AID1631954Stability in CD-1 mouse liver by LC-MS/MS analysis2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Design and Synthesis of Orally Bioavailable 4-Methyl Heteroaryldihydropyrimidine Based Hepatitis B Virus (HBV) Capsid Inhibitors.
AID1443830Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as decrease in HBV genome replication after 5 days by qPCR method2017Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8
Discovery and Pre-Clinical Characterization of Third-Generation 4-H Heteroaryldihydropyrimidine (HAP) Analogues as Hepatitis B Virus (HBV) Capsid Inhibitors.
AID1631930Drug metabolism in mouse liver microsomes assessed as aromatization of dihydropyrimidine core at 1 uM preincubated for 10 mins followed by NADPH addition measured up to 30 mins by LC-MS/MS analysis2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Design and Synthesis of Orally Bioavailable 4-Methyl Heteroaryldihydropyrimidine Based Hepatitis B Virus (HBV) Capsid Inhibitors.
AID1766984Antiviral activity against Human hepatitis B virus in Huh-7 cells assessed as reduction in intracellular viral DNA level incubated for 36 hrs by qPCR analysis
AID1631962Glutathione reactivity assessed as GSH adduct formation2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Design and Synthesis of Orally Bioavailable 4-Methyl Heteroaryldihydropyrimidine Based Hepatitis B Virus (HBV) Capsid Inhibitors.
AID1631934Selectivity index, ratio of CC50 for human HepDE19 cells to EC50 for Hepatitis B virus infected in human HepDE19 cells2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Design and Synthesis of Orally Bioavailable 4-Methyl Heteroaryldihydropyrimidine Based Hepatitis B Virus (HBV) Capsid Inhibitors.
AID1859032Antiviral activity against HBV infected in human HepDES19 cells assessed as reduction of capsid associated HBV DNA 2 uM measured by agarose gel electrophoresis-based particle gel assay2022Bioorganic & medicinal chemistry letters, 02-15, Volume: 584-Oxooctahydroquinoline-1(2H)-carboxamides as hepatitis B virus (HBV) capsid core protein assembly modulators.
AID1631929Drug metabolism in human liver microsomes assessed as aromatization of dihydropyrimidine core at 1 uM preincubated for 10 mins followed by NADPH addition measured up to 30 mins by LC-MS/MS analysis2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Design and Synthesis of Orally Bioavailable 4-Methyl Heteroaryldihydropyrimidine Based Hepatitis B Virus (HBV) Capsid Inhibitors.
AID1859026Antiviral activity against HBV infected in human HepDES19 cells assessed reduction of amounts of encapsidated pgRNA 2 uM measured after 24 hrs by northern blot hybridization assay2022Bioorganic & medicinal chemistry letters, 02-15, Volume: 584-Oxooctahydroquinoline-1(2H)-carboxamides as hepatitis B virus (HBV) capsid core protein assembly modulators.
AID1766981Inhibition of HBV recombinant Cp149 expressed in Escherichia coli BL21 (DE3) assessed as inhibition of capsid assembly at 10 uM incubated for 1 hr by immune blotting analysis relative to control
AID1443832Selectivity index, ratio of CC50 for HBV infected human HepDE19 cells to EC50 for HBV infected in human HepG2(2.2.15) cells2017Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8
Discovery and Pre-Clinical Characterization of Third-Generation 4-H Heteroaryldihydropyrimidine (HAP) Analogues as Hepatitis B Virus (HBV) Capsid Inhibitors.
AID1631937Aqueous solubility in 50 mM phosphate buffer at pH 6.5 after overnight incubation by HPLC based lyophilized solubility assay2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Design and Synthesis of Orally Bioavailable 4-Methyl Heteroaryldihydropyrimidine Based Hepatitis B Virus (HBV) Capsid Inhibitors.
AID1631933Cytotoxicity against human HepDE19 cells assessed as reduction in cell viability after 5 days by CCK8 assay2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Design and Synthesis of Orally Bioavailable 4-Methyl Heteroaryldihydropyrimidine Based Hepatitis B Virus (HBV) Capsid Inhibitors.
AID1725307Antiviral activity against Hepatitis B virus infected in human HepaRG cells assessed as inhibition of HBV DNA replication measured on day 11 post-infection by chemiluminescence immunostaining assay2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID1649769Antiviral activity against HBV infected in human HepG2.2.15 cells2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Discovery of (1
AID1661470Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as reduction in cytoplasmic HBV-DNA replication incubated for 8 days by real-time PCR analysis
AID1443831Cytotoxicity against HBV infected human HepDE19 cells assessed as decrease in cell viability after 5 days by CCK8 assay2017Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8
Discovery and Pre-Clinical Characterization of Third-Generation 4-H Heteroaryldihydropyrimidine (HAP) Analogues as Hepatitis B Virus (HBV) Capsid Inhibitors.
AID454487Therapeutic index, ratio of IC50 for human HepG2(2.2.15) cells to IC50 for HBV2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
2,4-Diaryl-4,6,7,8-tetrahydroquinazolin-5(1H)-one derivatives as anti-HBV agents targeting at capsid assembly.
AID1443833Solubility of compound in phosphate buffer at pH 6.5 after one night incubation by HPLC-UV method2017Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8
Discovery and Pre-Clinical Characterization of Third-Generation 4-H Heteroaryldihydropyrimidine (HAP) Analogues as Hepatitis B Virus (HBV) Capsid Inhibitors.
AID454486Cytotoxicity against human HepG2(2.2.15) cells2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
2,4-Diaryl-4,6,7,8-tetrahydroquinazolin-5(1H)-one derivatives as anti-HBV agents targeting at capsid assembly.
AID454485Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of viral DNA replication2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
2,4-Diaryl-4,6,7,8-tetrahydroquinazolin-5(1H)-one derivatives as anti-HBV agents targeting at capsid assembly.
AID1725312Cytotoxicity against human HepaRG cells assessed as effect on cell viability2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID1725311Half life in human primary hepatocytes at 1 uM measured up to 3 hrs under CYP450 restriction in presence of CYP450 inhibitiors ABT and SKF-525A by LC-MS/MS analysis2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID1725310Half life in human primary hepatocytes at 1 uM measured up to 3 hrs by LC-MS/MS analysis2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID1072514Antiviral activity against Hepatitis B virus assessed as inhibition of Hepatitis B virus DNA replication2014European journal of medicinal chemistry, Mar-21, Volume: 75A review of non-nucleoside anti-hepatitis B virus agents.
AID1725308Antiviral activity against Hepatitis B virus infected in human HepaRG cells assessed as inhibition of HBV DNA replication under CYP450 restriction pre-treated for 1 hr with CYP450 inhibitors ABT and SKF-525A on day 5 post-infection followed by removal of 2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID1444846Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA level2017Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15
Past, Current, and Future Developments of Therapeutic Agents for Treatment of Chronic Hepatitis B Virus Infection.
AID1661469Cytotoxicity in human HepG2.2.15 cells assessed as reduction in cell viability incubated for 8 days by MTT assay
AID1725309Ratio of EC50 for antiviral activity against Hepatitis B virus infected in human HepaRG cells assessed as fold change for inhibition of HBV DNA replication under normal condition to EC50 for inhibition of HBV DNA replication under CYP450 restriction pre-t2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID1353756Cytotoxicity against human HepG2.2.15 cells2018European journal of medicinal chemistry, Mar-10, Volume: 147Recent progress in potential anti-hepatitis B virus agents: Structural and pharmacological perspectives.
AID1502483Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of viral DNA level incubated for 3 days followed by medium replacement measured after 3 days by RT-PCR method
AID1353755Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as reduction in viral DNA level after 8 days by by dot-blot hybridization assay2018European journal of medicinal chemistry, Mar-10, Volume: 147Recent progress in potential anti-hepatitis B virus agents: Structural and pharmacological perspectives.
AID1859029Antiviral activity against HBV infected in human HepDES19 cells assessed as reduction in levels of intracellular core protein 2 uM measured by Western blot assay2022Bioorganic & medicinal chemistry letters, 02-15, Volume: 584-Oxooctahydroquinoline-1(2H)-carboxamides as hepatitis B virus (HBV) capsid core protein assembly modulators.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (28)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (21.43)29.6817
2010's14 (50.00)24.3611
2020's8 (28.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.04

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.04 (24.57)
Research Supply Index3.40 (2.92)
Research Growth Index4.81 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.04)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (10.34%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (89.66%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]